Yourgene Health PLC Opening of New Facilities and Corporate HQ
November 28 2019 - 2:01AM
RNS Non-Regulatory
TIDMYGEN
Yourgene Health PLC
28 November 2019
Yourgene Health plc
("Yourgene" or the "Group" or the "Company")
Opening of New Facilities and Corporate HQ
Manchester, UK - 28 November 2019: Yourgene (AIM: YGEN), a
leading international molecular diagnostics group, announces the
official opening of its newly integrated facilities and corporate
HQ at Citylabs 1.0, in the centre of Manchester's genomics campus,
and continued expansion with a planned further increase in
headcount at the Company's UK headquarters.
The establishment of the new Company head office at Citylabs
1.0, Nelson Street, Manchester, M13 9NQ, in the centre of
Manchester's genomics campus, is part of the ongoing integration of
the Elucigene acquisition which completed in April 2019. Citylabs
is based on a joint venture partnership between Manchester Science
Partnerships, the UK's leading science and technology park
operator, and Manchester University NHS Foundation Trust, the UK's
largest NHS provider Trust, and is the only development of its kind
in the UK. The Citylabs campus, currently undergoing a GBP95m
expansion, is surrounded by Manchester's leading hospitals and
makes it part of Europe's largest clinical-academic campus.
Following the acquisition of Elucigene, all departments are
being combined into a single management structure and manufacturing
concentrated onto the one site and the new facility is already
generating a strong cultural alignment across the enlarged Group.
Plans for process, systems and regulatory harmonisation are well
advanced and will be completed by the end of the financial year in
March 2020.
Yourgene Health currently employs 125 staff around the world,
with 89 staff now based at the enlarged UK headquarters in
Manchester. The Company has aspirations to grow staff numbers to
support the business growth anticipated over the next few years.
The Company is currently recruiting new staff in Manchester and has
opportunities for talented individuals with relevant scientific
backgrounds and commercial experience:
https://www.yourgene-health.com/contact-us/recruitment
Lyn Rees, CEO of Yourgene Health plc, said: "I am delighted at
the progress we've made to integrate the Elucigene acquisition, and
the opening of our new facilities and HQ at Citylabs, in the heart
of Manchester's exciting genomics hub, marks a new stage of growth
for our business. Together we have cultivated a dynamic fast-paced
culture offering a great opportunity to work with class leading
products and be part of developing and commercialising the next
generation of products to improve patient health globally. Citylabs
provides us with world-class facilities to operate from and a
vibrant place to work for our team."
Yourgene Health plc Tel: +44 (0)161 669 8122
Lyn Rees, Chief Executive Officer investors@yourgene-health.com
Barry Hextall, Chief Financial Officer
Joanne Cross, Director of Marketing
Stifel Nicolaus Europe Limited (Sole Tel: +44 (0)20 7710 7600
Corporate Broker)
Nicholas Moore / Matthew Blawat / Ben
Maddison
Walbrook PR Ltd (Media and Investor Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com
Relations) Mob: 07980 541 893 Mob: 07584 391 303
Paul McManus / Lianne Cawthorne
About Yourgene Health
Yourgene Health is an international molecular diagnostics group
which develops and commercialises genetic products and services.
The group works in partnership with global leaders in DNA
technology to advance diagnostic science.
Yourgene develops and commercialises simple and accurate
molecular diagnostic solutions, primarily for reproductive health.
The Group's products include non-invasive prenatal tests (NIPT) for
Down's Syndrome and other genetic disorders, Cystic Fibrosis
screening tests, invasive rapid aneuploidy tests, male infertility
tests and genetic disease tests. Yourgene's commercial footprint is
already established in the UK, Europe, the Middle East, Africa and
Asia.
Our product development, research service and commercial
capabilities extend across the lifecycle of genetic test
development including regulatory submissions. Through our technical
expertise and partnerships, Yourgene Health is also extending its
genetic testing offering into oncology.
Yourgene Health is headquartered in Manchester, UK with offices
in Taipei and Singapore, and is listed on the London Stock
Exchange's AIM market under the ticker "YGEN". For more
information, visit www.yourgene-health.com and follow us on twitter
@Yourgene_Health.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAUBAARKNAAUUA
(END) Dow Jones Newswires
November 28, 2019 02:01 ET (07:01 GMT)
Premaitha (LSE:NIPT)
Historical Stock Chart
From Sep 2024 to Oct 2024
Premaitha (LSE:NIPT)
Historical Stock Chart
From Oct 2023 to Oct 2024